Shire’s stalker raises its offer

US pharmaceuticals group AbbVie has made a fourth attempt to bag London-listed Shire Pharmaceuticals.

US pharmaceuticals group AbbVie has made a fourth attempt to bag London-listed Shire Pharmaceuticals. Its latest unsolicited bid is worth £30bn, or just over £51 a share an 11% improvement on the previous bid.

AbbVie urged Shire's shareholders to persuade the board to enter talks. AbbVie is best known for Humira, a rheumatoid arthritis drug. Shire specialises in drugs for attention deficit hyperactivity disorder.

What the commentators said

Back then, it was easy to point out that Pfizer was keen to take over Astra largely for tax purposes: it would keep its bills down by moving its domicile to the UK.

But this situation is different. While so-called tax inversion plays a part in AbbVie's motives, "Shire's role as a UK pharmaceutical powerhouse is undermined" by its own tax exile in Ireland, said Brummer; it has been based there for eight years. If AbbVie takes it over, Shire will actually come home.

In any case, Shire has never been a "research and development champion" in the Astra or GlaxoSmithKline mould.It has expanded largely by acquisition.

Plenty of shareholders will be happy with the offer, said Nils Pratley in The Guardian the shares traded at £35 before the bid surfaced. But AbbVie can pay more. Bank of America reckons it could stretch to £59 and still break even.

Shire's own growth target will also bolster its defences, said Navid Malik of Cenkos. It plans to double revenue by 2020, achievable given its "track record of building value". "Its value as a stand-alone company is very compelling."

Recommended

The US Federal Reserve is about to rein in its money-printing – what does that mean for markets?
US Economy

The US Federal Reserve is about to rein in its money-printing – what does that mean for markets?

America’s central bank is talking surprisingly tough about tightening monetary policy. And it’s not the only one. John Stepek looks at what it all mea…
23 Sep 2021
The end of the bond bull market, and how to invest for it
Investment strategy

The end of the bond bull market, and how to invest for it

The great bond bull market looks to be over, and you probably don’t want to be holding government bonds, says Merryn Somerset Webb. Here’s what you sh…
21 Sep 2021
Three strong Asian stocks trading at bargain prices
Share tips

Three strong Asian stocks trading at bargain prices

Professional investor Nitin Bajaj of the Fidelity Asian Values investment trust picks three stocks that dominate their industries, earn good returns o…
20 Sep 2021
Kieran Heinemann: the history of shareholder capitalism
Investment strategy

Kieran Heinemann: the history of shareholder capitalism

Merryn talks to Kieran Heinemann, author of Playing the Market: Retail Investment and Speculation in Twentieth-Century Britain, about the history of t…
17 Sep 2021

Most Popular

The times may be changing, but don’t change how you invest
Small cap stocks

The times may be changing, but don’t change how you invest

We are living in strange times. But the basics of investing remain the same: buy fairly-priced stocks that can provide an income. And there are few be…
13 Sep 2021
Two shipping funds to buy for steady income
Investment trusts

Two shipping funds to buy for steady income

Returns from owning ships are volatile, but these two investment trusts are trying to make the sector less risky.
7 Sep 2021
How to stop recurring subscriptions becoming a drain on your money
Personal finance

How to stop recurring subscriptions becoming a drain on your money

Tracking and pruning subscriptions isn’t as easy as it sounds. Here's how to take charge.
14 Sep 2021